Absorption enhancers for intranasal interferon administration
A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
1. A method of increasing absorption of interferon into the cerebrospinal fluid (CSF) of a subject comprising administering intranasally, interferon and an absorption increasing amount of a suitable nontoxic, nonionic alkyl glycoside, wherein the alkyl glycoside is dodecyl-β-D-maltoside.
2. The method of claim 1 , wherein the alkyl glycoside has a concentration in the range of about 0.01% to 1.0%.
3. The method of claim 1 , wherein the alkyl glycoside further has a hydrophile-lipophile balance number in the range of about 10 to 20.
4. The method of claim 1 , and further comprising administering a protease or peptidase inhibitor.
5. The method of claim 1 , wherein the compound is administered in a format selected from the group consisting of a drop, a spray, an aerosol and a sustained-release format.
6. The method of claim 1 , wherein the interferon is interferon-alpha, interferon-beta or interferon-gamma.
7. The method of claim 1 , wherein the method further comprises administering a mucosal delivery-enhancing agent selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof.